IDirect HealthCheck Jul16

Monthly Update
July 15, 2016
Health Check
Sector View
Neutral
USFDA plant clearances on the rise
Index Performance as on July 13, 2016

Return (%)
Return (%)
1M
3M
YTD
1Y
CNX 500
Nifty
NSE Pharma
-3
-9
Stocks Performance
Mcap
Return (%)
Company
1M
3M
Sun Pharma.Inds.
YTD
1Y
13-Jul
-8
-6
Lupin
14
-10
-14
74521
Dr Reddy's Labs
60903
-16 185436
15
15
15
-5
Aurobindo Pharma
-1
-12
45324
Cipla
-21
-23
41271
Cadila Health.
15
14
12
-4
37515
Divi's Lab.
14
24
31027
Glaxosmit Pharma
-6
29688
Torrent Pharma.
-3
-1
24134
10
-8
-19
23967
Glenmark Pharma.
Apollo Hospitals
-6
19146
Biocon
30
39
52
14377
Ajanta Pharma
21
14168
Alembic Pharma
-15
-23
11161
Wockhardt
-8
-38
-36
10515
Strides Arcolab
-10
-7
10391
Natco Pharma
13
30
28
10120
Pfizer
12
-18
-8
8875
Syngene Int.
18
NA
8430
Ipca Labs.
-5
-37
-32
5919
Jubilant Life
-12
-22
-25
56
4904
Unichem Labs.
19
31
Unichem Labs.
19
31
Indoco Remedies
Market cap in | crore
Price movement
15000
14000
13000
12000
11000
10000
9000
8000
7000
6000
5000
Jul-15
Oct-15
Jan-16
CNX Pharma
Research Analyst
Siddhant Khandekar
siddhant.khandekar@icicisecurities.com
Mitesh Shah
mitesh.sha@icicisecurities.com
In the last two or three months, there was a marked increase in the receipt
of Establishment Inspection Reports (EIR) from the USFDA. EIR receipt
indicates that the facility is in compliance with cGMP standards required by
the USFDA. Among our covered companies, Cadilas Moraiya
manufacturing facility received EIR from the USFDA. Lupins Goa facility
also received EIR with respect to the July 2015 inspection. However, the
March 2016 inspection observations (483) are still pending. Alembic also
received EIR for Karakahadi API III plant, which was inspected in April 2015.
On the Q1FY17 earnings front, we expect companies under I-Direct
healthcare to deliver YoY growth of 12.4% on a consolidated basis to
| 38162 crore. US sales from the select pack are expected to grow 27.6% to
| 12750 crore on the back of 1) rupee depreciation vis--vis US$ (5.5%
YoY), 2) exclusivity launches (gGleevec by Sun, gGlumetza by Lupin)
3) consolidation of acquisitions and 4) incremental product launches & price
hikes (gFortamet by Lupin). However, increased competition in existing
products, especially in gAbilify and price erosions, elsewhere, have partly
offset overall US growth. Domestic formulations from the select pack are
likely to grow ~5.2% YoY to | 7770 crore. NLEM and FDC related issues are
likely to impact domestic growth in Q1. Also, currency headwinds in
emerging economies such as Russia, Brazil, Venezuela and some African
countries will impact the overall performance negatively. We expect the
EBITDA of the I-direct healthcare coverage to grow ~14% YoY to | 10017
crore. EBITDA margins are likely to remain strong at ~26% YoY due to a
better product mix. We expect the net profit of the I-direct healthcare
coverage to grow 19.9% YoY to | 6267 crore mainly due to a strong
operational performance and lower taxation.
The Indian pharmaceutical market (IPM) grew 7.7% in June 2016. The
growth was mainly driven by price hikes 5.0%, and new product launches
11
30
2692
2.9%, while volumes declined 4.4%. The lower growth was mainly
11
30
2692
attributable to channel disturbances on account of 1) Fixed Dosage
-12
-21
2645 M Combinations (FDC) ban imposed by the government on 344 drugs as
despite stay by the Delhi HC, some state governments continued with the
order, 2) New price list for NLEM drugs based on WPI, which was negative
in FY16 and 3) new additions in NLEM 2015 list.
12000
Pharma in metamorphosis mode; valuations reflect near term headwinds
10000
After enjoying a near seamless journey in the US, thanks to the patent cliff
ride, the companies are facing headwinds not only in the US but also in
8000
India and some important emerging markets as discussed earlier. By virtue
6000
of this, most stocks are down 20-40% from their FY16 peaks. The
companies are bracing for the new normal whereby frequent and random
4000
USFDA audits will be common, so will be the cost on remediation and
Apr-16
Jul-16
improvement besides capex for alternate arrangements. Secondly, the R&D
Nifty (RHS)
spend is likely to spike as companies prepare for complex launches in the
US such as oncology injectables, respiratory, derma, ophthalmic and
biosimilars to mitigate the pricing impact and consolidation. However, this
metamorphosis is fraught with front-loaded costs and longer gestation
periods. We prefer companies that are best placed to tackle new challenges.
Our top picks are Lupin, Dr Reddys, Aurobindo, Torrent Pharma, Natco and
Syngene. Although there was a rise in EIRs recently, we believe USFDA,
NLEM and FDCs related issues are likely to weigh in the near term.
ICICI Securities Ltd. | Retail Equity Research
Regulatory approvals
Exhibit 1: Summary of USFDA approvals for June, 2016
Company
Aurobindo Pharma
Jubilant Life
Aurobindo Pharma
Aurobindo Pharma
Cadila Healthcare
Natco Pharma
Lupin
Unichem
Glenmark Pharma
Taro Pharma
Drug Name
Hydrocodone Bitartrate And Ibuprofen
Levetiracetam
Amiodarone Hydrochloride
Minocycline Hydrochloride
Gemfibrozil
Glycopyrrolate tablets
Estradiol and Norethindrone Acetate
Donepezil Hydrochloride
Nystatin; Triamcinolone Acetonide
Adapalene gel
Company
Taro Pharma
Aurobindo Pharma
Aurobindo Pharma
Aurobindo Pharma
Sun Pharma
Glenmark Pharma
Drug Name
BETAMETHASONE VALERATE
Pregabalin tablets
Omeprazole
Efavirenz
Dalfampridine
Olmesartan Medoxomil
Final Approvals
Therapeutic Area
Pain Management
Epilepsy
CVS
Anti-biotic
CVS
Anti-Ulcerent
OC
CNS
Derma
Derma
Tentative Approvals
Therapeutic Area
Dermatology
CNS
Gastro Intestinal
Antivirtal
Multiple Sclerosis
CVS
Innovator company
Abbvie
Ucb
Wyeth Pharms
Medicis
Pfizer
Merz Pharms
Amneal Pharma
Eisai Inc.
G And W Labs
Galderma Lab
Generic Version of
Vicoprofen
Keppra
Cordarone
Solodyn
Lopid
Cuvposa
Activella
Aricept
Mykacet
Differin
Market Size
NA
NA
NA
NA
US$ 44 million
NA
US$ 95.6 million
US$ 52.3 million
US$ 37.5 million
NA
Innovator company
G And W Labs
Forest
Astrazeneca
Bristol Myers Squibb
Acorda
Daiichi Sankyo
Generic Version of
BETA-VAL
Lyrica
Prilosec
Sustiva
Ampyra
Benicar
Market Size
NA
NA
US$ 185 million
US$ 150 million
NA
NA
[5
CNS: Central Nervous System; CVS: Cardiovascular,GI: Gastro Intestinal, NA: Not available;
Source: USFDA, ICICIdirect.com Research
M&As, demergers, tie-ups and JVs
Cipla in pact with Russian firm for HIV, Hepatitis C drugs

Cipla has inked a pact with Russia's National Immunobiological Company
(Nacimbio) to collaborate on HIV and Hepatitis C drugs, entailing an
investment of 2.8 billion roubles (~| 290 crore). As per Nacimbio, the
company will finalise construction and validation of the manufacturing plant
in 2017 and products will start to get commercialised from 2018.
Cadila Healthcare acquires two ANDAs from Teva
Cadila Healthcare has acquired two ANDAs from Teva that are being
divested as a pre-condition to its acquisition of Allergan's generic business.
The acquisition would be financed through internal accruals. One product
has already been commercialised while the other is in the pipeline
(Transdermal patch). The market size of the two ANDAs is ~US$200 million.
Apollo Hospitals ties up with HESCG to develop hospital in China
Apollo Hospitals has signed an agreement with Chinese infrastructure firm
Hainan Ecological Smart City Group (HESCG) to jointly develop an
integrated modern healthcare services facility and systems China. HESCG
will provide land and funding for the construction, commissioning and
equipping the hospital while Apollo will be responsible for planning and
commissioning, besides handling the operations and management of the
hospital and other related facilities.
Torrent Pharma to acquire Glochem's Vizag-based API unit
Torrent Pharma will acquire the Vizag API manufacturing facility of Glochem
Industries along with a few DMFs as a slump sale on a going concern basis.
The API unit was approved by USFDA and European regulatory authorities
and will be used by Torrent Pharma for vertical integration of its ANDA
filings in the future. The facility currently has three blocks for advanced
intermediates manufacturing and four blocks for API manufacturing.
Page 2
Aurobindo Pharma said to enter fray for $1.5 billion Teva portfolio
As per media sources, Aurobindo Pharma is considering joining the race to
buy assets of over US$1 billion from Teva that are being divested by the
Israel-based company in the UK, Ireland and Iceland as a precondition to
Tevas acquisition of Allergan generic business.
Price cuts, new launches, recalls, approvals
NPPA cuts prices of 42 drugs

NPPA has fixed/revised ceiling prices of 45 scheduled formulations of
Schedule-I under Drugs (Price Control) Amendment Order, 2016. Out of the
45, it has capped the prices of 42 essential medicines by reducing their cost
by ~15%. The capped drugs are used in the treatment of various ailments
including tuberculosis, cancer, cardiac diseases, tuberculosis, asthma,
epilepsy, rheumatoid arthritis and depression.
Lupin, DRL recall drugs in US over deviated results
Lupin Pharma is recalling 59,520 bottles of Lisinopril and Hydrochlorothiazid
tablets from US due to deviation from current good manufacturing practice
(CGMP). DRL is also recalling 84,240 bottles of Famotidine 10 mg tablets
due to an out of specification results has been determined for an individual
related substance during stability testing. As per the report, all the recalls
are fall under a class III recall category.
DRL recalls 9,330 bottles of Sirolimus tablets in US
DRL is recalling 9,330 bottles of Sirolimus tablets, used for prevention of
organ rejection after kidney transplant, in the US due to presence of
impurities. This recalls is fall under a class III recall category.
Cadila to launch AG of Asacol HD in US
Cadila Healthcare will start selling authorised generic (AG) of Asacol HD
(mesalamine delayed release) in the US from August 1, 2016. This drug is
used to treat a certain bowel disease (ulcerative colitis).
Biocons Insulin Glargine Launched in Japan
Biocons Japanese partner Fujufilm Pharma (FFP) has launched Insulin
Glargine in Japan. The company has received approval for its Insulin
Glargine from the Japanese regulator in March 2016. Insulin Glargine BS
Injection Kit (FFP) has been developed and manufactured by Biocon, and is
being commercialised by FFP in Japan. The product is a ready-to-use,
prefilled disposable pen with 3 ml of 100IU Insulin Glargine.
Lawsuits, court rulings, settlements, regulatory issues
Government relaxes FDI norms in pharma

The government has relaxed FDI policy norms for the pharma sector.
According to these norms, up to 74% FDI under the automatic route in
brownfield projects will be allowed (from 49% earlier) while government
approval would be needed beyond 74%.
Bombay HC imposes stay order on government move to cap drug prices
The Bombay High Court has imposed an interim stay on the government's
decision to further cut prices over the negative WPI of 530 drugs. The court
said companies need not take any further price cuts over WPI, which would
be under the revision of the national list of essential medicines.
Page 3
Medicines Patent Pool (MPP) has signed nine new sub-licensing agreements
Medicines Patent Pool (MPP) has signed nine new sub-licensing agreements
including Aurobindo, Lupin and Cadila for the generic manufacturing of HIV
and hepatitis C (daclatasvir) treatments. The agreement sub-licences to
produce and sell anti-retroviral drugs and Daclatasvir in 112 low and middle
income countries.
Cadila receives EIR for Moraiya Facility
Cadilas Moraiya manufacturing facility has received an Establishment
Inspection Report (EIR) from the USFDA. EIR indicates closure of the
inspection points (483s) raised based on the inspection carried out between
August 28, 2014 and September 05, 2014. Though this is a positive step
towards the resolution of the warning letter, it does not indicate resolution
of the warning letter. The company is still following up with the USFDA for
resolution of the warning letter.
Lupin receives EIR from US for Goa, July 2015
Lupin has received Establishment Inspection Reports (EIR) from USFDA for
Goa facility, which was inspected in July 2015. However, observations from
the March 2016 inspection for the same plant are still being reviewed.
Lupin Dabhasa unit gets two observations; voluntary action indicated only
Lupins Dabhasa facility has received two Form 483 observations from
USFDA. The plant was inspected by USFDA from June 29 to July 6, 2016.
The inspection has been classified as voluntary action indicated (VAI).
Alembic received EIR from USFDA for Karakhadi API unit
Alembic has received an Establishment Inspection Report (EIR) from USFDA
for Karakahadi API III plant, which was inspected in April 2015.
Others
Crisil downgrades Ipcas long term debt rating

Crisil has reduced Ipcas long term debt and non-convertible debenture
rating to AA -/Stable (from AA/Negative) while it has reaffirmed Ipcas short
term debt rating (A1+ rating).
Page 4
Exhibit 2: Patent litigations (12 months)

Innovator
Month
Jul-15
Eli Lilly
Jul-15
Fresenius Medical
Jul-15
Alcon Research
Aug-15
Allergan
Aug-15
Galderma Labs
Sep-15
Jazz Pharma
Sep-15
Gilead Sciences Inc.
Sep-15
Horizon Pharma
Sep-15
Bayer Pharma
Oct-15
Merck
Oct-15
Salix Pharmaceuticals, Inc.
Oct-15
Takeda Pharma
Oct-15
Janssen Pharma
Oct-15
Novartis Pharma
Oct-15
Otsuka Pharma
Oct-15
AstraZeneca
Nov-15
AstraZeneca
Nov-15
Novartis Pharma
Nov-15
Allergan
Nov-15
Shire Pharma
Nov-15
Dexcel Pharma
Nov-15
Dexcel Pharma
Nov-15
Cephalon Inc.
Nov-15
Cosmo Techs
Nov-15
Pfizer
Nov-15
Vanda Pharma
Nov-15
Forest Labs
Nov-15
Jazz Pharma
Nov-15
Otsuka Pharma
Nov-15
Symed Labs
Dec-15
UCB Inc.
Dec-15
Unimed Pharma
Dec-15
Helsinn Healthcare
Dec-15
Sanofi-Aventis
Dec-15
Otsuka Pharma
Dec-15
Merz Pharma
Jan-16
Dow Pharma
Jan-16
Cubist Pharma
Feb-16
Bayer Pharma
Feb-16
Bristol Myers Squibb
Feb-16
Janssen Products LP
Mar-16
Shire Canada
Mar-16
Daiichi Sankyo
Apr-16
Daiichi Sankyo
May-16
Daiichi Sankyo
Jun-16
Apicore
Jun-16
UCB, Inc.
Jun-16
Gilead
Jun-16
Janssen Biotech
Jun-16
Sanofi-Aventis
Source: Bloomberg, ICICIdirect.com Research
ANDA Filer
Brand Name
Lupin
Gavis Pharma
Lupin
Lupin
Taro Pharma
Lupin
Lupin
Lupin
Alembic Pharma
Lupin
Taro Pharma
Aurobindo
Aurobindo
Natco Pharma
Zydus Pharma
Alembic Pharma
InvaGen Pharma
Dr. Reddy's Labs
Aurobindo Pharma
Lupin
Sun Pharma
Dr. Reddy's Labs
Aurobindo Pharma
Lupin
Dr. Reddy's Labs
Lupin
InvaGen Pharma
Sun Pharma
Alkem Labs
Glenmark Pharma
InvaGen Pharma
Dr. Reddy's Labs
Dr. Reddy's Labs
Glenmark Pharma
Ajanta Pharma
Taro Pharma
Taro Pharma
Dr. Reddy's Labs
InvaGen Pharma
Cipla
Lupin
Lupin
Torrent Pharma
Alembic Pharma
Aurobindo Pharma
Aurobindo Pharma
Aurobindo Pharma
Aurobindo Pharma
Glenmark Pharma
Cadila Healthcare
Axiron
Phoslo
TravatanZ
Namenda
Epiduo
Xyrem
Tamiflu
Pennsaid
Staxyn
Beyaz
Moviprep
Prevacid
Xarelto
Gleevec
Abilify
Brilinta
Brilinta
Exelon Patch
Acular LS
Lialda
Omeprazole
Omeprazole
Nuvigili
Uceris
Toviaz
Fanapt
Viibryd
Xyrem
Abilify
Zyvox
Zyrtec-D
Androgel
Aloxi
Multaq
Abilify
Naftin
Onexton
Cubicin
Xarelto
Reyataz
Prezista
Daliresp
Benicar
Benicar
Benicar
LYMPHAZURIN
VIMPAT
EMTRIVA
ZYTIGA
MOZOBIL
API
Hypogonadism
Calcium Acetate
Travoprost Ophthalmic solution
Memantine Hydrochoride
Adapalene & Benzoyl peroxide
Sodium Oxybate
Oseltamivir
Diclofenac
Vardenafil Hydrochloride
Drospirenone
Polyethylene glycol electrolyte soln
lansoprazole
Rivaroxaban
Matinib Mesylate
Aripiprazole
Ticagrelor
Ticagrelor
Rivastigmine
Ketorolactromethamine
Mesalamine
Omeprazole
Omeprazole
Modafinil
Budesonide
Fesoterodine
Iloperidone
Vilazodone
Gamma-hydroxybutyric acid
Aripiprazole
Linezolid
Cetirizine
Testosterone
Palanosetron
Dronedarone
Aripiprazole
Naftifine Hydrochloride
Cindamycin Phosphate and Benzoyl Peroxide
Daptomycin
Rivaroxaban
Atazanavir
Darunavir
Roflumilast
Olmesartan
Olmesartan
Olmesartan
isosulfan blue
lacosamide
emtricitabine
abiraterone
plerixafor
Used for
Testosterone
Kidney Disease
Elevated Intraocular pressure
Alzheimer's Disease
Acne
Narcolepsy
Influenza
Osteoarthritis
Sex Stimulant
Birth control
Gastro Intestinal
Stomach ulcers
Blood Thinner
Anti-cancer
Schizophrenia
CVS
CVS
Dementia
Ocular Pain
Ulcerative Colitis
GI
GI
CNS
GI
Urotherapy
Schizophrenia
Anti-depressant
CNS
Schizophrenia
Anti-Infective
Respiratory
Low Testosterone
Nausea
Atrial Fibrillation
Schizophrenia
Fungal Infection
Acne
Antibiotic
Blood Thinner
HIV
HIV
Respiratory
Anti-depressant
Anti-depressant
Anti-depressant
lymphatic imaging agent
partial-onset seizures
HIV
Oncology
non-Hodgkin's lymphoma
[5
Page 5
Jun-16
May-16
Apr-16
Mar-16
6.4
8.1
3.8
6.7
9.7
9.7
20
Feb-16
Jan-16
12.5
10.6
10
Dec-15
Nov-15
23.0Oct-15
Sep-15
Aug-15
15
5
0
-5
Indian Pharma Market
Source: AIOCD data base, ICICIdirect.com Research
Source: AIOCD data base ; As per AIOCD MAT June 2016

(%)
7.1
Unichem
Torrent
Sun Pharma
3.6
Pfizer
Ipca Labs
4.0
3.5
1.1
4.7
11.5
9.1
11.4 11.3
Novartis
10
Lupin
15
Indoco
GSK Pharma
Glenmark
DRL
Cipla
Cadila
Exhibit 4: Companies growth in domestic market in June, 2016

Biocon
SubChronic,
20240.24,
20.2%
13.7
20
Ajanta
Acute,
48126.05,
48.1%
Jul-15
25
Industry acute to chronic therapy ratio percentage

Chronic,
31651.12,
31.6%
12.9
Exhibit 3: Domestic formulations - growth trend
Alembic
Brand
Company Therapy
June' 16 June' 15 Gr. (%)
Corex
Pfizer
Respiratory
319.8
240.1
33.2
Spasmo Prox Wockhardt GI
309.0
215.2
43.6
Augmentin GSK
Anti-Infectives 302.5
329.6
-8.2
Lantus
Sanofi
Anti Diabetic
291.5
235.5
23.8
Galvus Met Novartis
Anti Diabetic
290.6
199.7
45.5
Clavam
Alkem
Anti-Infectives 245.3
224.7
9.2
Volini
Ranbaxy
Pain
230.1
206.3
11.5
Becosules Sun Pharma Vitamins
219.8
255.6 -14.0
Foracort
Cipla
Respiratory
200.7
179.3
12.0
Pan
Alkem
GI
200.5
177.9
12.7
Source: AIOCD data base
The Indian pharmaceutical market (IPM) grew 6.4% YoY to | 8460 crore
in June. The growth was mainly driven by price hikes - 3.8%, and new
product launches - 3.2% while volumes declined 0.6%
The fixed dosage combination (FDCs) related market de-grew 14.6% to
| 186 crore
Drugs under the NLEM list declined 1.5% to | 963 crore while nonNLEM drugs posted growth of 8% to | 7120 crore. Volume growth in
NLEM was 3% while it declined 1.5% in non-NLEM
Among companies under I-direct coverage, Indoco, Ajanta and Alembic
registered decent growth of 11.5%, 11.4% and 11.3%, respectively.
Cipla, Glenmark, Lupin and Sun registered growth of 9.1%, 7.1%. 4.7%,
and 3.6%, respectively, while among the worst performers Torrent
Pharma de-grew 2.7%
Therapy wise, 10 therapies have outpaced the IPM growth. Notable
among them with growth rates- anti diabetic 11.7%, Urology 9.4%,
Gastro 8.8%, Derma 8.8%, Ophthal 8.8% and Respiratory8.2%.
In all, 324 new brands were launched in June 2016
On a MAT basis, IPM growth was at 10.6% YoY to | 100017 crore.
Domestic companies have grown 7.6% while MNC companies have
grown 2.0% in June 2016
Jun-15
Top brands in Indian pharma market
15.3
Therapy
June' 16 June' 15 YoY (%) May' 16 MoM (%)
Anti-Infectives
1162
1124
3.4
1165
-0.3
Cardiac
1061
1021
3.9
1097
-3.3
Gastro Intestinal
1088
1000
8.8
1063
2.3
Vitamins / Minerals /
806
758
6.4
794
1.5
Anti Diabetic
736
659
11.7
751
-2.0
Respiratory
530
490
8.2
526
0.8
Pain / Analgesics
576
557
3.5
575
0.2
Neuro / Cns
524
498
5.2
538
-2.7
Derma
519
479
8.5
516
0.7
Gynaecological
448
419
7.1
446
0.6
Ophthal / Otologicals
159
147
8.4
163
-2.2
Hormones
136
133
2.2
144
-6.0
Vaccines
133
142
-6.3
135
-1.3
Anti-Neoplastics
145
134
7.8
133
8.8
Blood Related
103
101
1.5
105
-1.8
Others
116
87
33.6
110
4.9
Urology
100
92
9.4
101
-0.8
Sex Stimulants / Reju
45
43
4.6
46
-1.8
Anti Malarials
35
36
-2.4
33
7.9
Stomatologicals
37
35
5.1
37
0.0
IPM grows 6.4% in June
(%)
Therapy wise performance (| crore)
7.0
3.6
1.5
0
-0.9
-5
-10
-2.7
-6.7
Page 6
Therapy wise performance (| crore)
The Indian pharmaceutical market (IPM) grew 6.4% YoY to | 25411

crore in Q1FY17. The growth was mainly driven by price hikes- 4.4%,
and new product launches- 3.1% while volumes declined 1.0%
The fixed dosage combination (FDCs) related market de-grew 15.2% to
| 580 crore
Drugs under the NLEM list declined 0.2% to | 2989 crore while nonNLEM drugs posted growth of 7.5% to | 21240 crore. Volume growth in
NLEM was 0.4% while the decline was 3.4% in non-NLEM
Among companies under I-Direct coverage Ajanta, Alembic and
Glenmark registered decent growth of 10.7%, 9.4% and 8.2%,
respectively. Cipla, Sun and DRL registered growth of 5.7%, 4.8% and
1.1%, respectively, while, among the worst performers Lupin and
Torrent Pharma de-grew 1.0% and 1.5%, respectively
Therapy wise, 12 therapies have outpaced IPM growth. Notable among
them with growth rates- Anti diabetic 14.5%, Urology 10.6%, Derma
8.6%, CNS 8.5% and Cardiac8.1%.
Exhibit 5: Domestic formulations - quarterly growth trend
(%)
Therapy
Q1FY17 Q1FY16 YoY (%) Q4FY16 QoQ (%)
Anti-Infectives
3497
3448
1.4
3568
-2.0
Cardiac
3266
3021
8.1
3132
4.3
Gastro Intestinal
3209
2995
7.1
2777
15.6
Vitamins / Minerals /
2374
2215
7.2
2048
15.9
Anti Diabetic
2225
1943
14.5
2039
9.1
Respiratory
1633
1613
1.2
2056 -20.6
Pain / Analgesics
1728
1668
3.6
1618
6.8
Neuro / Cns
1601
1475
8.5
1543
3.8
Derma
1550
1428
8.6
1454
6.6
Gynaecological
1335
1253
6.6
1211
10.2
Ophthal / Otologicals
486
450
8.0
436
11.5
Hormones
419
397
5.4
417
0.5
Vaccines
400
409
-2.2
373
7.3
Anti-Neoplastics
399
411
-2.9
355
12.4
Blood Related
306
287
6.7
262
17.0
Others
330
249
32.4
270
22.3
Urology
302
273
10.6
260
16.2
Sex Stimulants / Reju
140
130
7.3
145
-3.8
Anti Malarials
100
111
-10.1
94
7.0
Stomatologicals
110
102
8.4
99
11.8
IPM grows 6.4% in Q1FY17
19.0
17.0
15.0
13.0
11.0
9.0
7.0
5.0
3.0
1.0
-1.0
-3.0
16.8
13.6
1.5
10.8
1.1
0.1
3.3
10.9
4.6
9.6
14.8
3.3
5.2
3.3
4.8
8.4
6.6
2.5
Q1FY15 Q2FY15
Q3FY15 Q4FY15
Volumes
11.9
3.0
9.3
3.0
5.0
1QFY16
Price Increases
6.4
2.9
4.6
5.1
7.5
14.7
3.1
5.0
6.7
4.2
4.4
1.4
2QFY16 3QFY16
-1.0
4QFY16 1QFY17
New Products
[
(%)
12.0
10.0
8.0
6.0
4.0
2.0
(2.0)
(4.0)
(6.0)
9.4
6.8
Unichem
Torrent
Sun Pharma
Sanofi
Pfizer
Novartis
Lupin
Ipca
Indoco
Glenmark
GSK Pharma
Dr Reddy's
Cipla
Biocon
10.7
Alembic
Ajanta
Exhibit 6: Company wise growth trends in Q1FY17
8.2
5.7
5.2
5.5
3.7
5.3
4.8
3.0
1.1
1.1
(1.0)
(1.5)
(4.3)
Page 7
Sun Pharmaceuticals
Acute : Chronic contribution (MAT June16)
Stock Performance
Chronic,
3959.54,
45.3%
150
130
110
90
70
50
SubChronic,
1195.58,
13.7%
Acute,
3582.85,
41.0%
Jul-15
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
May-16
Jul-16
Sun Pharma
Source: NSE, ICICIdirect.com Research
11 to 20
21 to 30
31 to 50
Others
Jun-16
May-16
Apr-16
Mar-16
Feb-16
12.3
18.8
6.4
3.6
5.6
3.8
5.2
8.1
6.7
12.3
9.7
Exhibit 9: Top 10 brands performance
9.6
8.9
8.9 8.9 9.0 8.8 8.9 8.9

8.7 8.7
(| crore)
Brand
Therapy
Volini
Pain
June' 16 June' 15 Var. (%) May' 16 Var. (%)

19.3
14.7
31.1
20.5
-5.9
Rosuvas
Cardiac
17.2
12.7
35.2
16.4
4.8
Istamet
Anti Diabetic
15.4
13.1
17.5
14.8
4.1
7.8
Gemer
Anti Diabetic
14.7
13.5
9.3
14.2
4.1
7.2
Levipil
Neuro
14.3
12.2
17.2
12.9
10.3
6.6
Susten
Gynaecological
13.2
13.2
-0.5
13.9
-5.2
Pantocid
Gastro Intestinal
11.6
11.9
-2.7
12.0
-3.6
Revital H
Vitamins
10.8
6.7
61.0
11.7
-7.5
Pantocid Dsr
Gastro Intestinal
10.0
10.2
-2.4
10.3
-3.4
Storvas
Cardiac
9.7
10.3
-5.5
10.5
-7.5
8.4
(%)
Sun Pharmaceutical Industries
Exhibit 8: Market share in Indian formulations market
9.2
6.7
8.2
9.0
Jan-16
12.5
9.7
3.1
5
0
Top 10
Dec-15
Nov-15
23.0Oct-15
10.6
10.8
10
10.0
(%)
7%
10%
13.7
15
9%
57%
15.3
21.7
20
17%
12.9
15.9
25
16.6
Sep-15
Aug-15
Jun-15
Brands contribution to domestic sales (MAT June16)
Jul-15
Exhibit 7: Company growth vis--vis Indian pharma market growth
8.4 8.3 8.3
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
Jul-15
Jun-15
6.0
Sun Pharmaceutical Industries
Source: AIOCD data base, ICICIdirect.com Research * Included Ranbaxys sales
Exhibit 10: Contribution of therapies to domestic sales (MAT June16)
Exhibit 11: Therapy wise performance
Derma
7%
Cardiac
29%
Anti-Infectives
18%
Gastro
Intestinal
19%
Neuro
27%
Therapy
Cardiac
Neuro
(| crore)
June' 16
141.6
June' 15
132.5
YoY (%)
6.9
May' 16
144.9
QoQ (%)
-2.3
130.1
124.8
4.3
132.9
-2.1
Gastro Intestinal
92.9
92.1
0.9
91.7
1.4
Anti-Infectives
80.1
79.2
1.1
79.4
0.9
Derma
37.4
34.2
9.3
70.4
-46.9
Anti Diabetic
69.5
68.2
1.9
52.9
31.2
Gynaecological
30.5
31.4
-2.9
38.2
-20.1
Pain
54.2
51.3
5.7
29.5
83.6
Respiratory
23.6
23.1
2.0
31.2
-24.6
Vitamins
32.8
30.0
9.1
23.4
40.0
Page 8
Cipla
July 15, 2016
Stock Performance
Chronic,
1975.31,
39.8%
140
120
100
80
60
SubChronic,
620.67,
12.5%
Acute,
2370.80,
47.7%
Jul-15
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
Jul-16
Cipla
Others
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
6.4
9.1
6.4
3.8
6.7
8.1
12.3
10.0
11.6
9.7
12.5
16.7
2.1
31 to 50
3.5
21 to 30
4.6
5
11 to 20
9.7
15.9
21.0
13.7
10.6
10
12.9
15
11.1
8%
11.6
(%)
12%
23.0Oct-15
Sep-15
Aug-15
Jun-15
20
44%
15.3
16.7
25
24%
12%
Jul-15
Top 10
May-16
Cipla

(| crore)
5.4
Brand
Therapy
5.2
Foracort
Respiratory
16.4
14.6
12.1
16.6
-1.2
Budecort
Respiratory
10.7
9.9
8.3
12.9
-16.6
Asthalin
Respiratory
9.6
9.9
-3.1
9.7
-0.2
Seroflo
Respiratory
10.4
10.5
-0.5
10.5
-0.4
Duolin
Respiratory
10.2
8.7
16.7
9.5
7.6
5.1
5.0
4.8
(%)
4.8
5.2
5.1
5.2
5.0 4.9
5.2
4.9
4.8 4.8
4.6 4.7
4.6
4.4
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
Jul-15
Jun-15
4.2
Cipla
Aerocort
Respiratory
7.3
7.3
0.3
7.6
-3.2
Azee
Anti-Infectives
6.2
6.9
-10.7
5.3
15.1
Montair Lc
Respiratory
5.8
5.1
13.2
6.3
-8.0
Novamox
Anti-Infectives
5.2
5.9
-12.3
5.6
-6.4
Emeset
Gastro Intestinal
6.8
6.3
7.5
6.2
8.9
Other
19%
Urology
5%
Gastro
Intestinal
8%
Cardiac
12%
Respiratory
29%
Anti-Infectives
27%
Therapy
Respiratory
Ant i- Infect iv es
(| crore)
June' 16
111.1
102.9
June' 15
100.7
95.5
YoY (%)
10.4
7.7
May' 16
113.1
102.3
Q oQ (%)
-1.8
0.5
Cardiac
51.4
Gas tro Intes tinal
38.5
48.8
5.2
52.7
-2.5
32.7
17.6
35.0
Urology
Neuro
19.9
14.2
9.8
18.6
15.2
7.2
-6.6
20.0
14.6
-0.5
-2.7
-5.9
Ophthal
14.4
13.3
8.6
15.3
Pain
13.0
10.2
27.0
12.8
1.6
Derma
Vitamins
10.4
9.2
9.8
7.4
6.3
24.9
10.1
8.5
3.1
8.1
Dr. Reddys Labs

Chronic,
716.58,
30.1%
Acute,
1177.47,
49.4%
Stock Performance) Stock Performance

140
120
100
80
60
SubChronic,
489.83,
20.5%
Jul-15
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
May-16
Jul-16
Dr. Reddys
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
Jun-15
Jul-15
11 to 20
21 to 30
31 to 50
Others
1.5
6.4
8.1
-1.5
3.4
3.8
6.7
2.9
2.7
2.7
2.4
2.3 2.3
2.3
2.2
2.3
2.6
2.6
2.5
2.3
2.1
2.2 2.2 2.3
1.9
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
Jul-15
1.7
Jun-15
Dr. Reddys Laboratories
(%)
31.6
-10
2.5
12.3
9.7
26.6
27.6
12.5
9.7
6.7
0
Top 10
23.8
23.0
30.9
10.6
7.8
10
13.7
(%)
12% 9%
15.1
20
16%
12.9
27.2
30
15.3
29%
34%
31.9
40
Dr. Reddys Laboratories
Gastro
Intestinal
22%
Cardiac
14%
Anti-Infectives
8%
Respiratory
9%
Therapy
Omez
Gastro Intestinal
10.6
10.8
-1.3
10.9
-2.5
Omez D
Gastro Intestinal
8.8
7.5
17.2
7.4
19.7
Econorm
Gastro Intestinal
7.4
6.2
19.4
6.2
19.0
Stamlo
Cardiac
4.2
5.2
-19.0
4.9
-15.2
Grafeel
Anti-Neoplastics
2.4
5.2
-53.1
5.6
-56.3
Nise
Pain
4.9
4.3
12.5
5.4
-9.4
Razo D
Gastro Intestinal
5.3
4.5
18.3
4.4
20.3
Mintop
Derma
3.7
3.4
9.2
3.5
6.0
Razo
Gastro Intestinal
4.3
4.1
5.8
3.9
10.5
Reditux
Anti-Neoplastics
4.1
5.1
-18.1
3.2
29.1

Other
36%
(| crore)
Brand
AntiNeoplastics
11%

Therapy
Gastro Intestinal
(| crore)
June' 16
47.1
June' 15
45.7
YoY (%)
3.1
May' 16
42.8
QoQ (%)
9.9
Cardiac
26.1
31.2
-16.5
26.6
-1.8
Anti-Neoplastics
22.7
18.4
23.6
20.5
11.0
14.3
Respiratory
15.5
13.7
13.9
13.6
Anti-Infectives
14.5
12.8
13.5
13.9
4.2
Derma
12.4
13.3
-6.5
12.2
1.8
Pain
13.0
13.9
-6.4
12.5
3.7
Anti Diabetic
13.1
14.0
-6.1
13.3
-1.5
Urology
8.3
8.1
3.3
7.6
9.6
Stomatologicals
6.6
6.8
-3.5
6.4
3.5
Page 10
Lupin
Stock Performance
Chronic,
1643.67,
49.0%
140
120
100
80
60
SubChronic,
651.19,
19.4%
Acute,
1057.53,
31.5%
Jul-15
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
May-16
Jul-16
Lupin
Jun-16
May-16
Apr-16
Mar-16
8.1
20.5
-4.4
-4
-2.8
3.8
6.4
4.7
6.7
12.3
18.4
Feb-16
Jan-16
9.7
13.0
12.5
14.4
9.7
Dec-15
Nov-15
23.0 Oct-15
7.1
2.6
8.4
(%)
13% 9%
12.0
12
11%
10.6
13.7
20.8
20
20%
12.9
47%
15.3
28
21.7
Sep-15
Aug-15
Jun-15
Jul-15
-12
Top 10
11 to 20
21 to 30
31 to 50
Others

Brand
3.7
3.5
3.3 3.2
3.4 3.4 3.4 3.4

3.3 3.4
3.4 3.3 3.3 3.3
3.2
Therapy
(| crore)
Gluconorm-G
Anti Diabetic
Tonact
Cardiac
13.4
10.8
24.7
14.3
-5.9
7.1
8.4
-15.1
8.4
-14.6
4.3
-5.7
3.8
6.5
2.5
Rablet
Gastro Intestinal
4.1
4.6
-10.6
4.1
0.0
2.3
Ramistar
Cardiac
3.4
4.3
-20.4
3.7
-7.3
-1.3
Jun-16
4.0
May-16
Respiratory
Apr-16
Esiflo
Mar-16
2.7
Feb-16
-3.8
Jan-16
-1.3
4.8
Dec-15
7.3
1.7
Nov-15
22.1
4.6
Oct-15
5.9
4.6
Sep-15
7.2
Gastro Intestinal
Aug-15
Respiratory
Rablet-D
Jul-15
Budamate
2.9
3.1
Jun-15
(%)
3.3
Lupin
Lupin
R-Cinex
Anti-Infectives
3.7
3.4
8.6
3.7
Cetil
Anti-Infectives
3.9
3.0
27.9
3.8
0.2
Tazar
Anti-Infectives
3.6
3.3
6.9
3.5
2.9
Other
22%
Cardiac
26%
Gastro
Intestinal
8%
Anti Diabetic
11%
Anti-Infectives
21%
Respiratory
12%
Therapy
Cardiac
(| crore)
June' 16
66.3
June' 15
67.8
YoY (%)
-2.3
May' 16
72.2
QoQ (%)
-8.2
Anti-Infectives
54.7
54.9
-0.3
55.2
-0.8
Respiratory
30.9
29.0
6.6
31.8
-2.8
Anti Diabetic
34.8
27.6
25.9
36.4
-4.3
Gastro Intestinal
22.8
21.8
4.6
22.8
-0.1
Vitamins
14.9
16.8
-11.3
15.7
-4.6
Neuro
13.9
12.8
8.2
14.7
-5.4
Pain
12.2
12.6
-3.3
12.7
-3.7
Gynaecological
10.6
9.0
17.5
10.6
0.0
2.1
1.8
16.1
2.3
-6.7
Ophthal
Page 11
Cadila Healthcare
Stock Performance
Chronic,
1643.67,
49.0%
140
120
100
80
60
SubChronic,
651.19,
19.4%
Acute,
1057.53,
31.5%
Jul-15
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
May-16
Jul-16
Cadila Healthcare
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Aug-15
13.7
16.8
Oct-15
Jul-15
12.9
16.9
Sep-15
Jun-15
15.3
17.6
3.8
6.4
6.7
8.1
12.3
11.7
9.7
7.5
Others
1.1
31 to 50
5.8
21 to 30
3.0
11 to 20
7.1
Top 10
7.3
10
12.5
15
11.3
(%)
13% 9%
9.7
20
11%
18.8
25
20%
10.6
47%
23.0
27.2
30
Cadila Healthcare
4.0
3.9
3.9
4.0
3.9
3.9 3.9
3.9
Jun-16
Apr-16
Mar-16
3.8
Feb-16
Nov-15
Sep-15
Aug-15
Jul-15
Oct-15
3.9
Jan-16
4.0
3.9
Dec-15
4.0
May-16
4.1
4.1
4.0
4.0
3.9
3.9
3.8
3.8
3.7
3.7
Jun-15
(%)
Cadila Healthcare
(| crore)
Brand
Therapy
Skinlite
Derma
15.3
13.7
11.2
16.3
-6.4
Atorva
Cardiac
7.8
10.9
-28.3
11.0
-28.8
Mifegest Kit
Gynaecological
11.0
9.1
21.0
10.4
5.5
Deriphyllin
Respiratory
7.5
7.7
-2.3
8.1
-7.3
Pantodac
Gastro Intestinal
9.6
8.3
15.4
9.5
1.6
Falcigo
Anti Malarials
3.8
6.3
-40.7
3.5
8.7
Amlodac
Cardiac
5.3
6.8
-22.0
5.4
-1.8
Aten
Cardiac
5.0
6.9
-27.1
5.3
-5.2
Zyrop
Blood Related
6.3
5.8
8.4
8.6
-26.8
Clopitorva
Cardiac
4.5
4.8
-6.5
5.0
-10.3
Other
38%
Therapy
Cardiac
Cardiac
16%
Gastro
Intestinal
14%
Gynaecological
11%
Pain
10%
Respiratory
11%
(| crore)
June' 16
49.7
June' 15
56.8
YoY (%)
-12.5
May' 16
55.6
QoQ (%)
-10.6
Gastro Intestinal
48.5
42.6
13.9
47.3
2.7
Gynaecological
33.5
37.0
-9.6
34.6
-3.2
Respiratory
29.8
29.1
2.5
31.0
-3.8
Pain
31.3
28.7
8.9
32.3
-3.0
Derma
26.9
24.8
8.6
26.9
-0.1
Anti-Infectives
22.6
22.0
3.1
23.4
-3.4
Anti-Neoplastics
22.1
18.6
19.0
20.6
7.2
Vitamins
14.7
13.0
12.6
14.4
2.0
5.0
6.8
-26.0
4.7
7.9
Anti Malarials
Page 12
GlaxoSmithKline
Stock Performance
Chronic,
424.60,
13.1%
SubChronic,
700.87,
21.7%
Acute,
2108.18,
65.2%
140
120
100
80
60
Jul-15
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
May-16
GSK Pharma
31 to 50
Jun-16
6.4
-6.7
21 to 30
0.3
-6.4
-3.5
3.8
6.7
8.1
12.3
6.9
9.7
9.9
-5
11 to 20
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
12.5
11.9
9.7
9.9
5.8
2.8
1.3
10.6
10
16%
4.9
(%)
13.7
15
51%
9%
12.9
20
15.3
25
10%
Nov-15
23.0
27.2
30
14%
Oct-15
Sep-15
Aug-15
Jun-15
Jul-15
Top 10
Jul-16
-10
Others
Glaxosmithkline Pharmaceuticals


3.6
3.5
3.4
3.3
3.4 3.4
3.3
Brand
Therapy
Augmentin
Anti-Infectives
(| crore)

16.7
26.5
-36.9
20.5
-18.7
-11.4
Synflorix
Vaccines
16.4
14.3
14.7
18.5
Calpol
Pain
13.8
13.3
3.3
13.1
5.3
Zinetac
Gastro Intestinal
13.5
12.5
8.4
15.0
-10.0
2.6
Betnovate C
Derma
10.2
11.9
-14.5
11.0
-7.1
2.4
Betnovate N
Derma
10.1
12.4
-18.6
11.5
-12.6
Rotarix
Vaccines
8.7
5.7
52.4
10.0
-13.1
Eltroxin
Hormones
11.9
10.9
9.2
12.7
-6.7
Ceftum
Anti-Infectives
10.1
11.7
-13.3
9.9
1.6
Betnesol
Hormones
5.9
7.9
-25.7
6.6
-11.1
3.2
(%)
3.3
3.4
3.2
3.1 3.1
3.0
3.0 3.1
2.9
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
Jul-15
Jun-15
2.8
Glaxosmithkline Pharmaceuticals

Anti-Infectives
23%
Other
26%
Respiratory
8%
Pain
9%
Derma
19%
Vaccines
15%

Therapy
Anti-Infectives
(| crore)
June' 16
51.6
June' 15
57.0
YoY (%)
-9.5
May' 16
53.7
QoQ (%)
-3.9
Derma
45.3
56.4
-19.7
49.2
-7.9
Vaccines
39.4
38.0
3.8
44.5
-11.3
Pain
23.6
21.7
8.7
23.7
-0.3
Respiratory
16.4
16.0
2.7
17.5
-6.2
Hormones
18.3
20.4
-10.2
19.9
-8.2
Vitamins
22.0
21.7
1.4
21.1
4.4
Gastro Intestinal
15.3
13.9
10.0
17.0
-10.1
Cardiac
4.5
5.8
-21.4
4.8
-4.5
Gynaecological
3.2
2.9
12.9
3.5
-6.7
Page 13
Wockhardt
Stock Performance
Chronic,
266.61,
19.8%
Acute,
926.55,
68.9%
400
350
300
250
200
150
100
50
0
SubChronic,
150.77,
11.2%
Jul-15
Nov-15
Jan-16
Mar-16
CNX Pharma
May-16
Jul-16
Wockhardt
Jun-16
Apr-16
3.8
4.8
May-16
Mar-16
6.7
2.5
Feb-16
Jan-16
1.8
6.4
8.1
9.4
9.7
12.5
12.3
29.7
38.3
9.7
10
Others
5.5
31 to 50
9.9
21 to 30
10.6
15.3
(%)
20
23.0
36.0
30
14%
42.2
40
56%
Dec-15
50.4
50
8%
Nov-15
Oct-15
Sep-15
Aug-15
13.7
24.4
60
8%
11 to 20
Jul-15
Jun-15
14%
12.9
29.2
Top 10
Sep-15
0
Wockhardt

Brand
1.8
1.7
1.6
1.5
1.4
1.3
1.2
1.1
1.0
Therapy
24.7
29.9
-17.4
22.5
9.9
Vitamins
7.9
6.5
21.1
8.9
-11.9
Tryptomer
Neuro
5.4
5.0
6.4
5.8
-7.1
Bro Zedex
Respiratory
2.9
3.1
-5.6
3.2
-9.5
Methycobal
Vitamins
4.9
4.2
15.1
4.9
0.4
Biovac V
Vaccines
2.3
6.2
-62.9
3.0
-23.9
Biovac A
Vaccines
2.0
4.2
-53.1
2.5
-21.3
Zedex
Respiratory
2.0
2.2
-9.0
2.0
0.6
Practin
1.23
Jun-16
1.29
1.26
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
Jul-15
1.28
1.41 1.39
1.37 1.38 1.35
1.37 1.35 1.39
1.34
Wockhardt
(| crore)
Spasmo Proxyvon PluGastro Intestinal
Jun-15
(%)
Ace Proxyvon
Pain
2.2
2.8
-23.3
2.2
-0.6
Wosulin
Anti Diabetic
2.4
2.0
20.6
3.0
-19.0
Exhibit 40: Contribution of therapies to domestic

sales (MAT June16)
Gastro
Intestinal
25%
Other
33%
Therapy
Gastro Intestinal
Vitamins
Respiratory
Neuro
Vitamins
15%
Anti-Infectives
7%
Neuro
8%
Respiratory
12%
Anti-Infectives
(| crore)
June' 16
27.0
June' 15
27.4
YoY (%)
-1.2
May' 16
24.8
QoQ (%)
9.0
19.2
16.0
19.7
20.5
-6.3
9.1
8.4
8.0
9.4
-2.9
10.0
7.4
35.9
10.6
-4.8
4.9
6.6
-25.4
5.6
-11.8
-1.8
Derma
7.4
6.6
12.6
7.5
Pain
7.5
6.3
18.3
6.9
7.9
Anti Diabetic
7.7
6.2
23.9
8.5
-9.6
Vaccines
4.3
8.9
-51.5
5.6
-22.6
Hormones
2.6
2.3
13.5
2.8
-3.9
Page 14
Glenmark Pharmaceuticals
Stock Performance
Chronic,
908.04,
37.6%
200
180
160
140
120
100
80
60
SubChronic,
563.30,
23.3%
Acute,
945.56,
39.1%
Jul-15
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
Jul-16
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
6.4
8.1
6.7
14.8
12.3
19.7
9.7
16.3
13.1
9.7
12.5
18.6
23.0
43.6
Oct-15
Sep-15
10.6
30.9
34.6
7.1
Others
8.9
31 to 50
3.8
8.7
21 to 30
11.5
11 to 20
13.7
28.1
13%
10%
12.9
13%
Aug-15
Jun-15
(%)
35%
15.3
29%
50
45
40
35
30
25
20
15
10
5
0
Jul-15
Top 10
May-16
Glenmark

Therapy
Telma
Cardiac
12.5
14.8
Telma H
Cardiac
12.1
Ascoril Plus
Respiratory
7.1
Candid
Derma
2.1
Candid-B
Derma
Telma Am
1.9
Ascoril Ls
2.7
2.5
2.4 2.3
2.3
2.3
2.5 2.5
2.4
2.6
2.5
2.4 2.4
2.4
2.3
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
Jul-15
2.2
Jun-15
(%)
(| crore)
Brand

Anti Diabetic
8%
Derma
30%
Anti-Infectives
13%
Respiratory
15%
-15.8
13.6
-7.9
11.4
6.1
12.7
-4.8
7.5
-5.9
5.7
23.9
11.1
8.8
25.6
10.6
4.6
8.5
8.3
2.6
7.5
14.4
Cardiac
6.3
6.1
2.9
6.8
-7.9
Respiratory
2.5
2.9
-12.1
2.6
-1.8
Zitamet
Anti Diabetic
0.1
7.0
-98.3
0.2
-26.8
Onabet
Derma
3.8
3.0
25.5
3.2
16.5
Zita(Glenmark)
Anti Diabetic
1.1
4.7
-77.3
1.5
-28.5
Other
11%
Cardiac
23%

Therapy
Derma
June' 16
63.8
(| crore)
June' 15
55.3
YoY (%)
15.3
May' 16
59.5
QoQ (%)
7.3
Cardiac
44.4
44.6
-0.4
46.6
-4.7
Respiratory
23.1
21.9
5.5
20.7
11.6
Anti-Infectives
26.1
24.3
7.4
22.9
13.7
Anti Diabetic
15.0
17.1
-12.1
15.1
-0.3
Vitamins
6.7
5.0
34.4
6.2
8.0
Gastro Intestinal
5.6
4.8
17.6
5.0
12.5
Pain
4.3
4.1
5.6
4.2
1.8
Gynaecological
3.5
3.4
3.4
3.7
-4.3
Ophthal
3.0
2.9
3.0
2.5
20.2
Page 15
Torrent Pharmaceuticals
Stock Performance
Chronic,
1156.47,
51.0%
200
160
120
80
40
SubChronic,
564.71,
24.9%
Acute,
545.88,
24.1%
Jul-15
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
May-16
Jul-16
Torrent Pharma
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
Jun-15
Jul-15
31 to 50
Others
6.4
1.4
2.4
3.8
6.7
8.1
12.3
10.2
9.7
-5
-2.7
21 to 30
-3.0
11 to 20
3.8
5.4
0
Top 10
12.5
19.9
7.4
10
9%
9.7
14%
12%
10.6
16.0
(%)
15
13.7
21.7
20
12.9
18.3
28.3
32%
15.3
25
33%
23.0
30
2.8
2.51
2.4
(%)
2.36
2.25 2.23
2.23
2.17 2.20
2.30
2.35
2.33 2.30
2.23 2.26
2.0
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
Jul-15
Jun-15
1.6
Cardiac
29%
Pain
8%
Gastro
Intestinal
15%
Vitamins
16%
Therapy
Shelcal
Vitamins
Chymoral Forte
Nikoran
Dilzem
(| crore)

17.4
20.2
-13.7
16.3
6.7
Pain
9.8
10.6
-7.4
9.6
2.1
Cardiac
7.1
6.5
9.5
7.3
-2.6
Cardiac
5.3
5.1
5.0
5.9
-10.1
Nebicard
Cardiac
5.0
5.0
0.9
5.4
-6.7
Azulix-Mf
Anti Diabetic
5.4
4.8
13.5
5.8
-5.3
Nexpro Rd
Gastro Intestinal
4.6
4.3
8.6
4.4
5.4
Nexpro
Gastro Intestinal
4.2
4.1
3.5
4.0
6.6
Shelcal Ct
Vitamins
4.2
2.6
59.2
4.5
-8.1
Alprax
Neuro
3.0
3.3
-9.0
3.2
-6.1

Other
16%
Brand
Neuro
16%

Therapy
Cardiac
June' 16
54.2
(| crore)
June' 15
57.4
YoY (%)
-5.5
May' 16
58.0
QoQ (%)
-6.6
Neuro
31.0
32.3
-4.1
32.1
-3.6
Vitamins
33.0
30.8
7.2
32.5
1.5
Gastro Intestinal
29.7
30.3
-2.0
28.2
5.1
Pain
15.8
15.5
1.5
15.7
0.5
Anti Diabetic
12.4
11.6
6.9
12.6
-2.2
Anti-Infectives
6.8
10.3
-34.1
6.2
9.2
Derma
5.4
4.5
17.8
5.2
3.6
Gynaecological
3.1
3.5
-11.5
3.1
-1.8
Urology
1.0
0.7
50.0
1.0
5.3
Page 16
Ipca Laboratories
Stock Performance
150
125
100
75
50
Chronic,
350.08,
27.5%
Acute,
843.66,
66.3%
SubChronic,
78.28, 6.2%
Jul-15
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
Ipca
21 to 30
31 to 50
Jun-16
May-16
Apr-16
Mar-16
6.4
8.1
4.0
3.7
3.3
3.8
6.7
1.5
11.5
9.1
1.5 1.4
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
1.3 1.2 1.2 1.2

1.2 1.2 1.2 1.2
Oct-15
Sep-15
Aug-15
1.3
1.2 1.3
Jul-15
Ipca Laboratories
Jun-15
12.3
9.7
12.5
11.8
-10
Others
(%)
Feb-16
Jan-16
Dec-15
Nov-15
9.7
6.3
-0.1
-5.5
0
-5
3.0
16%
10.6
10
3.6
(%)
11%
13.7
15
13%
12.9
20
37%
15.3
25
23%
11 to 20
23.0
25.8
30
Oct-15
Sep-15
Aug-15
Jun-15
Jul-15
2.0
1.8
1.6
1.4
1.2
1.0
0.8
0.6
Jul-16
Top 10
May-16
Ipca Laboratories
Anti-Infectives
6%
Brand
Therapy
Zerodol Sp
Pain
7.4
7.7
-3.3
7.5
-1.3
Zerodol P
Pain
5.4
5.2
4.9
5.9
-7.9
Hcqs
Anti Malarials
5.1
6.0
-15.7
5.5
-8.1
Larinate
Anti Malarials
2.9
3.4
-12.8
2.9
0.4
Rapither-Ab
Anti Malarials
2.8
4.0
-29.1
2.5
11.4
Glycinorm M
Anti Diabetic
3.0
3.1
-3.2
3.3
-10.5
Folitrax
Anti-Neoplastics
3.0
2.9
5.0
3.0
1.4
Lariago
Anti Malarials
1.6
2.2
-25.3
1.6
4.0
Zerodol
Pain
2.3
2.4
-4.2
2.3
1.3
Lumerax
Anti Malarials
1.6
2.1
-25.7
1.5
4.7
Pain
26%

Therapy
Pain
Anti Malarials
19%
Cardiac
17%
June' 16
26.5
(| crore)
June' 15
26.3
YoY (%)
0.7
May' 16
27.3
QoQ (%)
-3.1
Anti Malarials
16.4
15.5
6.0
15.8
4.2
Cardiac
18.7
17.8
4.9
19.0
-1.7
9.4
9.3
1.3
9.6
-2.5
Gastro Intestinal
Gastro
Intestinal
8%

Other
24%
(| crore)
Anti-Infectives
5.9
5.9
0.1
5.5
6.9
Anti Diabetic
5.4
5.2
4.3
5.8
-6.8
Respiratory
3.0
2.7
10.3
3.0
-1.1
Anti-Neoplastics
4.9
4.1
20.7
5.0
-1.4
Neuro
3.9
4.2
-8.7
3.7
3.7
Derma
3.1
3.0
4.3
2.7
16.7
Page 17
Biocon
Stock Performance
Chronic,
243.16,
71.2%
140
120
100
80
SubChronic,
29.19, 8.5%
Acute,
69.38,
20.3%
60
Jul-15
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
Jul-16
21 to 30
31 to 50
May-16
8.1
9.4
Jun-16
Apr-16
3.8
7.7
Mar-16
6.4
3.5
6.7
14.5
Feb-16
12.3
11.3
5.3
5.2
9.7
12.5
Jan-16
Dec-15
Nov-15
9.7
23.0
Oct-15
10.6
-5
-10
Others
-11.2
11 to 20
-0.8
2%
6.0
(%)
5%
7.3
10
6%
13.7
15
11%
4.8
76%
15.3
20
12.9
25
10.0
Sep-15
Aug-15
Jun-15
Jul-15
Top 10
May-16
Biocon
-15
Biocon

0.39
Brand
0.38
0.37
0.36
0.36
0.35
0.34
0.33
0.33
0.33
0.31
0.31
0.35 0.350.35
0.34
0.34
0.32
Therapy
(| crore)
Insugen
Anti Diabetic
7.3
7.5
-2.9
7.8
-7.3
Basalog
Anti Diabetic
5.2
5.0
3.9
5.3
-2.2
Erypro
Blood Related
2.3
2.3
1.4
2.4
-5.2
Canmab
Anti-Neoplastics
1.7
1.4
18.8
1.5
14.2
16.2
152.4
1.1
117.2
Biomab Egfr
Anti-Neoplastics
0.0
0.1
-100.0
1.0
-100.0
Insugen N
Anti Diabetic
0.6
0.9
-29.8
0.6
5.6
Psorid
Anti-Neoplastics
0.7
0.5
53.9
0.7
-1.8
Jun-16
0.9
May-16
2.3
Apr-16
Anti-Neoplastics
Mar-16
8.2
Abraxane
Feb-16
1.4
Jan-16
1.2
-2.6
Dec-15
-9.6
1.6
Nov-15
1.5
1.5
Oct-15
1.4
Anti Diabetic
Sep-15
Anti Diabetic
Insugen R
Jul-15
Blisto Mf
0.27
Aug-15
0.29
Jun-15
(%)
Biocon

Cardiac
5%
Blood Related
Derma
3%
Other
5%
6%
AntiNeoplastics
22%
Anti Diabetic
59%

Therapy
Anti Diabetic
(| crore)
June' 16
17.2
June' 15
16.3
YoY (%)
6.1
May' 16
17.6
Anti-Neoplastics
6.5
Blood Related
2.3
Cardiac
Derma
QoQ (%)
-2.0
5.5
18.2
6.1
7.9
2.7
-12.9
2.4
-4.8
1.5
1.8
-20.0
1.5
-4.5
0.9
0.8
12.7
0.7
27.6
Anti-Infectives
0.5
0.9
-38.4
0.4
47.3
Gastro Intestinal
0.1
0.1
38.4
0.1
1.9
Others
0.2
0.3
-14.9
0.3
-11.8
Vitamins
0.2
0.2
-3.2
0.1
47.0
Pain
0.0
0.0
-16.7
0.1
-62.7
Page 18
Pfizer
Stock Performance
Chronic,
454.57,
15.7%
SubChronic,
563.59,
19.4%
Acute,
1882.66,
64.9%
200
160
120
80
40
Jul-15
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
Pfizer
21 to 30
31 to 50
Jun-16
May-16
Apr-16
6.4
8.1
2.8
7.3
3.8
6.7
-0.9
Pfizer
3.2
2.94 2.97 2.94 2.91 2.94
2.91 2.92 2.93
2.8
2.84
2.89
2.96
2.85
2.74
2.6
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
Jul-15
2.4
Jun-15
3.5
5.1
-10
Others
(%)
Mar-16
12.3
9.7
-3.4
0
-5
11 to 20
Feb-16
Jan-16
Dec-15
12.5
3.5
19%
0.9
9.9
(%)
10
9.7
15
50%
10%
15.3
20.3
20
10%
10.6
25
11%
Nov-15
23.0
25.4
30
Oct-15
Aug-15
13.7
19.7
Sep-15
Jul-15
Jun-15
12.9
17.3
3.0
Jul-16
Top 10
May-16
Pfizer
(| crore)
Brand
Therapy
Corex
Respiratory
20.2
25.4
-20.4
22.4
Becosules
Vitamins
20.1
20.7
-3.1
19.1
4.9
Magnex
Anti-Infectives
11.1
13.4
-17.3
10.3
7.7
Gelusil Mps
Gastro Intestinal
10.5
12.4
-15.2
10.4
0.9
Dolonex
Pain
10.9
11.6
-6.4
11.3
-3.9
Minipress Xl
Cardiac
9.3
10.0
-7.2
12.3
-24.6
10.0
9.0
11.0
10.2
-2.7
8.0
7.0
13.6
8.9
-10.7
Mucaine
Gastro Intestinal
Wysolone
Hormones
Folvite
Blood Related
7.1
6.9
2.4
7.5
-5.4
Dalacin C
Anti-Infectives
5.4
6.8
-20.5
5.9
-9.0
Anti-Infectives
16%
Other
40%
Respiratory
14%
Gastro
Intestinal
11%
Hormones
9%
Vitamins
10%
-9.7
Therapy
Anti-Infectives
June' 16
32.2
(| crore)
June' 15
37.9
YoY (%)
-15.0
May' 16
32.5
QoQ (%)
-1.0
Respiratory
26.1
23.7
9.9
28.7
-9.2
Gastro Intestinal
25.9
25.4
2.1
26.3
-1.3
Vitamins
25.2
26.8
-6.0
24.6
2.6
Hormones
20.5
20.0
2.4
22.3
-8.2
-1.5
Gynaecological
20.5
17.8
15.2
20.8
Neuro
16.7
16.2
3.2
18.4
-9.2
Cardiac
15.4
18.5
-16.7
18.0
-14.5
Pain
15.5
15.8
-2.1
16.4
-5.5
7.6
7.3
3.7
7.9
-4.4
Blood Related
Page 19
Novartis
Stock Performance
Chronic,
503.68,
42.2%
190
140
90
SubChronic,
168.35,
14.1%
Acute,
520.86,
43.7%
40
Jul-15
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
Novartis India
31 to 50
Jun-16
May-16
Apr-16
Mar-16
6.4
8.1
3.6
3.8
3.7
4.2
5.5
9.5
6.7
9.7
-2.7
-2.0
0.0
Novartis India

1.3
1.24
1.22
1.2
(%)
12.3
12.5
7.8
Feb-16
Jan-16
Dec-15
Nov-15
9.7
10.6
-1.7
-5
Others
13.7
-1.0
4.2
78%
21 to 30
12.9
10
3.1
(%)
15
23.0Oct-15
Sep-15
Aug-15
Jun-15
20
15.3
25
2%
12% 4%4%
11 to 20
Jul-15
1.18
1.16
1.2
Jul-16
Top 10
May-16
1.20 1.20
1.19

1.22
1.23
1.18 1.18
1.131.13
1.1
Jun-16
Apr-16
May-16
Mar-16
Feb-16
Jan-16
Dec-15
Oct-15
Nov-15
Sep-15
Aug-15
Jul-15
Jun-15
1.1
Novartis India
(| crore)
Brand
Therapy
Galvus Met
Anti Diabetic
23.5
Voveran
Pain
16.8
Galvus
Anti Diabetic
9.9
Rabipur (Novartis)
Vaccines
7.9
Tegrital
Neuro
Voveran
Pain
Regestrone
Gynaecological
Methergin
-0.9
24.5
-4.2
16.2
3.7
18.0
-6.3
11.2
-11.4
9.7
1.7
7.9
0.0
6.4
23.8
4.3
5.0
-14.7
4.6
-7.1
3.3
3.2
3.2
3.3
1.8
2.7
3.2
-15.3
2.9
-6.7
Gynaecological
2.2
2.7
-15.8
2.2
1.5
Genteal
Ophthal
2.4
2.7
-9.2
2.4
1.9
Syntocinon
Gynaecological
2.3
1.9
21.2
2.3
2.7
Exhibit 70: Contribution ofOther

therapies to domestic sales (MAT June16)
17%
Anti Diabetic
35%
Gynaecological
8%
Vaccines
9%
Vitamins
10%
Pain
21%
Therapy
Anti Diabetic
23.7
(| crore)
June' 16
33.9
June' 15
29.9
YoY (%)
13.4
May' 16
34.8
Pain
21.7
Vitamins
11.5
Vaccines
Gynaecological
QoQ (%)
-2.6
18.7
16.0
22.8
-4.7
9.4
21.8
8.9
29.3
7.9
8.6
-7.4
6.4
25.0
7.5
7.9
-5.3
7.7
-2.2
Neuro
4.3
5.9
-26.7
4.6
-7.1
Anti-Infectives
2.7
4.3
-37.4
4.0
-32.6
Ophthal
2.6
3.3
-20.5
3.0
-13.2
Respiratory
1.6
1.6
-4.3
1.6
-3.0
Cardiac
0.8
1.1
-25.4
0.8
-2.1
Page 20
Unichem Laboratories
Stock Performance
Chronic,
528.17,
58.2%
160
130
100
70
Acute,
324.77,
35.8%
SubChronic,
55.19, 6.1%
Jul-15
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
May-16
Jul-16
Unichem Labs
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
Jun-15
Jul-15
11 to 20
21 to 30
31 to 50
12.3
6.4
7.0
5.3
3.8
3.5
2.1
5.6
5.2
6.7
8.1
9.7
11.0

Brand
1.10
0.970.98
0.97
0.92
0.90
0.94
0.89
0.88 0.87
0.88
0.86 0.87
0.89
0.93
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
Jul-15
0.80
Jun-15
(%)
9.7
Others
1.00
2.5
0
Top 10
10.6
2.7
0.6
13%
20.5
10
9%
13.7
15
11.1
(%)
11%
12.9
20
45%
15.3
25
22%
12.5
23.0
26.6
30
Neuro
14%
Losar H
Cardiac
8.7
6.9
26.0
8.4
3.6
Ampoxin
Anti-Infectives
5.2
5.3
-1.7
5.5
-4.9
Losar
Cardiac
5.8
5.6
2.7
5.6
3.1
Unienzyme
Gastro Intestinal
5.2
5.9
-12.3
6.2
-16.2
Vizylac
Gastro Intestinal
4.7
2.8
64.5
3.8
21.3
Trika
Neuro
1.9
2.2
-10.7
1.9
4.0
Serta
Neuro
2.0
1.9
7.5
2.0
0.2
Unistar (Unichem)
Cardiac
1.8
1.5
22.1
1.8
2.9
Telsar
Cardiac
1.5
1.5
-0.1
1.6
-4.2
Arkamin
Cardiac
1.5
1.2
28.3
1.4
2.3

Therapy
Cardiac
Other
11%
Gastro
Intestinal
12%
(| crore)

Pain
4%
Therapy
Cardiac
42%
Anti-Infectives
17%
(| crore)
June' 16
36.0
June' 15
31.5
YoY (%)
14.2
May' 16
35.3
QoQ (%)
1.9
Anti-Infectives
11.8
Neuro
11.0
13.1
-9.8
12.0
-1.8
9.8
12.4
10.8
2.0
Gastro Intestinal
-1.4
11.4
11.4
-0.8
11.5
Pain
3.4
3.0
13.3
3.3
2.0
Anti Diabetic
3.6
2.5
44.8
3.4
6.2
Vitamins
1.7
2.5
-30.6
1.8
-1.8
Respiratory
1.6
1.8
-11.8
1.6
3.4
Derma
2.0
1.2
59.6
2.0
0.2
Gynaecological
0.4
0.5
-22.9
0.4
3.7
Page 21
Indoco Remedies
Stock Performance
Acute,
575.31,
82.3%
140
120
100
80
60
Chronic,
41.04, 5.9%
SubChronic,
82.32,
11.8%
Jul-15
Sep-15
Nov-15
Indoco
11 to 20
31 to 50
-5
Others
Jun-16
May-16
Apr-16
Mar-16
Feb-16
6.4
11.5
5.2
3.8
-1.0
0.7
6.7
8.1
12.3
5.4
5.6
11.0
9.7
12.5
Jan-16
Dec-15
Nov-15
9.7
23.0Oct-15
10.6
-1.3
21 to 30
13.7
10.3
1.2
16%
3.7
(%)
10
9%
-6.4
47%
12.9
15
11%
16.2
Sep-15
Aug-15
Jul-15
Jun-15
15.3
20
17%
-10
Indoco Remedies

0.7
0.7
0.7 0.7 0.7
0.7 0.7 0.7
0.7
0.7
0.7
0.7
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
Jul-15
0.6
Jun-15
Jul-16
25
(%)
May-16
0.8
0.7
0.7
0.7
0.7
0.7
0.6
0.6
0.6
Mar-16
CNX Pharma
Top 10
Jan-16
Indoco Remedies
(| crore)
Brand
Therapy
Febrex Plus
Respiratory
4.8
5.4
-10.5
Cyclopam
Gastro Intestinal
4.3
4.5
Oxipod
Anti-Infectives
2.8
2.6
Cital
Urology
3.2
Sensodent-K
Stomatologicals
Atm
Anti-Infectives
Sensodent-Kf
Cloben G
4.2
14.5
-3.4
3.8
13.0
7.7
2.6
8.1
3.0
6.5
3.9
-16.3
3.2
2.8
14.4
3.0
3.7
2.1
2.1
0.3
1.9
14.5
Stomatologicals
1.7
2.0
-14.4
1.8
-4.4
Derma
2.0
2.0
1.9
1.9
8.6
Karvol Plus
Respiratory
1.0
1.0
6.6
1.0
5.1
Cyclopam
Gastro Intestinal
2.2
2.0
10.0
1.8
23.6

Other
27%
Anti-Infectives
18%

Therapy
Anti-Infectives
Respiratory
Respiratory
18%
Vitamins
7%
Gastro
Intestinal
14%
Stomatological
s
16%
June' 16
9.3
(| crore)
June' 15
7.8
YoY (%)
19.7
May' 16
8.7
QoQ (%)
6.9
13.6
8.1
7.4
8.5
7.1
Stomatologicals
10.2
9.0
13.2
9.9
2.9
Gastro Intestinal
9.9
8.8
12.1
8.5
16.5
Vitamins
4.8
4.3
13.1
4.7
4.0
-14.3
Urology
3.8
3.3
14.9
4.4
Ophthal
3.1
2.8
9.6
3.0
1.9
Derma
2.7
2.3
14.6
2.4
10.4
Pain
2.6
2.4
8.1
2.6
1.8
Anti Diabetic
1.9
1.8
5.3
1.9
-2.8
Page 22
Ajanta Pharmaceuticals
Stock Performance
Chronic,
238.66,
48.9%
290
240
190
140
90
40
SubChronic,
56.84,
11.6%
Acute,
192.80,
39.5%
Jul-15
Sep-15
Nov-15
Jan-16
Mar-16
CNX Pharma
Ajanta
25
23%
21 to 30
Jun-16
May-16
Apr-16
Mar-16
Feb-16
Jan-16
31 to 50
Others
6.4
8.1
11.4
13.1
6.9
3.8
7.6
6.7
7.6
9.7
12.3
10.5
12.5
14.3
5
11 to 20
Dec-15
Nov-15
9.7
6.5
9.9
10.9
10
12%
10.0
(%)
10.6
12.6
13.7
18.3
15
13%
12.9
15.3
20
42%
10%
23.0
Oct-15
Sep-15
Aug-15
Jun-15
Jul-15
0
Ajanta Pharma
(| crore)
Brand
Therapy
Met Xl
Cardiac
4.6
3.7
23.9
4.9
Melacare
Derma
3.0
3.6
-18.1
3.1
-5.4
Atorfit Cv
Cardiac
2.9
2.9
1.7
2.9
-0.3
Soft Drops
Ophthal
1.3
1.1
15.5
1.4
-8.6
Rosufit Cv
Cardiac
1.3
1.1
19.1
1.2
6.6
0.4
Feburic
Pain
1.1
1.1
-1.7
1.3
-9.9
0.4
Met Xl Am
Cardiac
1.2
0.9
30.8
1.2
-4.7
Cinod
Cardiac
0.9
0.7
22.7
0.9
-0.4
Rosutor Gold
Cardiac
1.0
0.6
70.1
0.9
17.5
Olopat
Ophthal
0.9
0.7
18.1
0.8
5.9
0.5
0.5
0.51 0.52
0.5
0.49
0.48 0.48 0.48
0.510.50
0.51
0.48 0.48
Jun-16
May-16
Apr-16
Mar-16
0.45
Feb-16
Oct-15
Sep-15
Aug-15
Jul-15
Jun-15
0.4
Jan-16
0.46
0.5
Dec-15
0.5
Nov-15
(%)
Jul-16
Top 10
May-16
Ajanta Pharma
Pain
5%
Vitamins
6%
Derma
22%
Others
9%
Cardiac
34%
Ophthal
24%
-7.1
(| crore)
Therapy
Cardiac
June' 16
15.5
June' 15
13.0
YoY (%)
19.0
May' 16
15.7
QoQ (%)
-1.2
Ophthal
10.4
9.1
14.3
10.8
-3.2
Derma
8.3
8.4
-1.4
8.4
-2.0
Vitamins
2.3
2.5
-8.4
2.2
4.7
Pain
1.9
2.1
-8.7
2.1
-7.9
Gastro Intestinal
1.0
1.1
-10.0
1.0
3.6
Neuro
0.9
0.8
12.0
0.9
6.7
Anti-Infectives
0.8
0.5
52.7
0.7
12.2
Anti Diabetic
0.6
0.0
NA
0.5
20.9
Respiratory
0.2
0.2
-1.4
0.2
4.0
Page 23
Alembic Pharmaceuticals
Stock Performance
Chronic,
302.59,
21.6%
200
180
160
140
120
100
80
60
40
SubChronic,
261.36,
18.6%
Acute,
839.15,
59.8%
Jul-15
Sep-15
Nov-15
Jan-16
CNX Pharma
May-16
Jul-16
Alembic Pharma
11 to 20
31 to 50
Others
Jun-16
May-16
Apr-16
Mar-16
Feb-16
6.4
11.3
8.1
11.4
3.8
5.7
6.7
8.1
12.3
13.7
23.1
12.5
19.0
6.1
21 to 30
9.7
10
14%
9.7
15
10.6
(%)
13%
13.7
21.5
25
20
10%
23.0
36%
24.1
30
27%
Jan-16
31.6
35
Dec-15
Nov-15
Oct-15
Sep-15
Jul-15
12.9
17.3
Aug-15
Jun-15
15.3
18.4
Top 10
Mar-16
Alembic Pharma


Brand
1.6
1.5
1.5
1.4
1.4
1.3
1.3
1.2
1.2
1.49 1.50 1.49

1.43 1.44
1.44
1.33
1.32 1.30 1.33
Apr-16
Mar-16
Feb-16
Jan-16
Dec-15
Nov-15
Oct-15
Sep-15
Aug-15
Jul-15
1.27
Jun-16
1.37
May-16
1.41
Jun-15
(%)
Alembic Pharma
Therapy
(| crore)
Azithral
Anti-Infectives
7.4
11.6
-35.8
8.7
-14.8
Althrocin
Anti-Infectives
6.4
6.9
-7.2
6.6
-3.7
Roxid
Anti-Infectives
4.3
4.4
-3.6
4.1
4.1
Gestofit
Gynaecological
5.4
4.8
13.1
5.3
2.1
Wikoryl
Respiratory
2.5
2.6
-3.1
2.5
-0.6
Ulgel
Gastro Intestinal
2.7
3.0
-10.1
2.7
0.4
Rekool D
Gastro Intestinal
2.6
3.0
-12.9
2.4
11.2
Rekool
Gastro Intestinal
2.2
2.2
-1.0
2.0
6.0
Zeet
Respiratory
1.3
1.6
-22.7
1.3
-3.4
Rekool L
Gastro Intestinal
2.1
2.1
-0.6
1.9
13.1
Other
24%
Anti-Infectives
24%
Gynaecological
11%
Therapy
Cardiac
14%
Gastro
Intestinal
14%
June' 15
YoY (%)
May' 16
QoQ (%)
Anti-Infectives
21.7
23.1
-6.1
22.8
Gastro Intestinal
16.8
15.3
9.7
15.9
5.4
Cardiac
17.6
14.3
22.5
16.8
4.7
-1.2
Respiratory
Respiratory
13%
June' 16
(| crore)
-4.9
9.6
9.5
1.4
9.7
Gynaecological
14.5
11.9
22.7
13.7
5.8
Vitamins
10.3
8.1
27.7
10.2
0.7
Anti Diabetic
8.1
6.4
27.1
7.6
7.0
Pain
4.5
4.1
8.7
4.7
-5.3
Urology
2.8
1.8
52.0
2.4
15.6
Derma
2.0
2.5
-20.8
2.0
-2.7
Page 24
ICICIdirect.com coverage universe (Healthcare)

CMP
(|)
TP
(|)
Rating
M Cap
(| Cr)
EPS (|)
PE(x)
EV/EBITDA (x)
RoCE (%)
RoE (%)
FY16P FY17E FY18E FY16P FY17E FY18E FY16P FY17E FY18E FY16P FY17E FY18E FY16P FY17E FY18E
Company
I-Direct
Code
Ajanta Pharma
AJAPHA 1602 1,780
Buy
14100.6
45.7
52.4
63.6
35.1
30.6
25.2
22.7
19.3
16.3
43.7
37.9
35.6
34.4
30.0
Apollo Hospitals
APOHOS 1371 1,420 Hold
19076.1
22.2
35.0
49.2
61.8
39.2
27.9
26.6
19.2
15.3
8.2
10.9
13.3
8.9
12.6
15.4
Aurobindo Pharma
AURPHA
774
990
Buy
45295.1
33.9
37.7
45.1
22.8
20.5
17.2
24.8
22.0
18.5
25.0
24.6
26.4
28.1
24.3
22.9
Alembic Pharma
ALEMPHA 585
620
Hold
11029.1
38.2
19.6
28.3
15.3
29.8
20.7
12.6
23.9
17.3
58.0
24.8
29.7
51.5
22.3
26.2
28.2
Biocon
BIOCON
713
545
Hold
14254.0
22.1
28.3
30.5
32.3
25.2
23.4
8.7
7.3
6.0
9.1
10.9
11.1
10.9
12.7
12.5
Cadila Healthcare
Cipla
CADHEA
CIPLA
364
511
390
470
Buy
Hold
37305.2
41056.2
15.0
18.8
15.5
19.9
20.6
26.2
24.4
27.2
23.5
25.6
17.7
19.5
14.2
16.6
14.1
14.8
10.8
11.8
27.9
12.1
24.6
13.1
29.5
16.0
28.6
12.7
24.4
12.1
26.3
14.1
Divi's Laboratories
DIVLAB
1156 1,260
Buy
30680.2
41.7
45.8
52.4
27.7
25.2
22.1
19.2
16.9
14.4
30.6
29.1
28.4
25.8
23.6
22.6
Dr Reddy's Labs
DRREDD 2974 3,480
Buy
61068.0
142.1 139.2 174.0
20.9
21.4
17.1
13.1
12.8
10.2
15.1
15.1
18.3
18.9
16.1
16.8
Glenmark Pharma
GLEPHA
858 1,000
Buy
23944.6
32.2
41.4
50.1
26.7
20.7
17.1
17.0
13.9
11.5
16.2
18.8
20.3
21.2
21.7
21.0
Indoco Remedies
INDREM
291
365
Buy
2677.9
9.3
15.1
20.4
31.2
19.2
14.3
16.1
11.6
9.2
13.2
19.7
24.4
14.7
20.9
24.2
Ipca Laboratories
Jubilant Life Sciences
Lupin
IPCLAB
469
455
Hold
5912.5
10.0
24.1
30.4
46.8
19.4
15.4
17.9
11.1
8.9
5.8
12.4
14.5
5.5
12.0
13.3
VAMORG
309
405
Buy
4920.0
26.0
41.6
56.1
11.9
7.4
5.5
7.6
6.1
4.8
12.0
15.1
17.8
14.2
18.9
20.6
1658 1,850
Buy
74752.0
50.4
66.0
74.1
32.9
25.1
22.4
19.4
13.5
11.8
18.6
22.5
23.1
20.7
22.1
19.9
Natco Pharma
NATPHA
LUPIN
581
600
Buy
10115.2
8.9
10.9
13.0
65.2
53.1
44.6
30.0
26.9
22.8
16.1
16.4
17.3
12.0
13.0
13.7
Sun Pharma
SUNPHA
770
785
Hold
185356.2
23.4
26.2
31.3
32.9
29.4
24.6
20.8
18.1
15.2
18.6
19.5
20.1
18.0
17.3
17.6
445
Syngene International
SYNINT
421
Buy
8425.0
8.8
11.1
15.6
43.3
34.2
24.3
26.1
20.5
16.7
19.5
13.3
16.7
20.7
21.2
23.5
Torrent Pharma
TORPHA
1440 1,650
Buy
24370.2
115.5
67.8
75.0
12.5
21.2
19.2
8.3
14.2
12.8
51.1
27.0
26.8
57.7
27.0
24.4
UNILAB
298
Buy
2711.2
12.3
15.5
22.1
24.2
19.2
13.5
14.5
11.6
8.3
13.8
16.2
20.4
11.7
13.4
16.8
310
Exhibit 92: One year forward P/E of CNX Pharma vs. Sensex
35
29.5%Premium
30
25
20
15
10
5
CNX Pharma
Jan-16
Jul-15
Jan-15
Jul-14
Jan-14
Jul-13
Jan-13
Jul-12
Jan-12
Jul-11
Jan-11
Jul-10
Jan-10
Jul-09
Jan-09
Jul-08
Jan-08
Jul-07
Jan-07
Jul-06
Sensex
[
Source: Company, ICICIdirect.com Research
Page 25
RATING RATIONALE
ICICIdirect.com endeavours to provide objective opinions and recommendations. ICICIdirect.com assigns

ratings to its stocks according to their notional target price vs. current market price and then categorises them
as Strong Buy, Buy, Add, Reduce and Sell. The performance horizon is two years unless specified and the
notional target price is defined as the analysts' valuation for a stock.
Sector view:
Over weight compared to index
Equal weight compared to index
Under weight compared to index
Index here refers to BSE 500
Pankaj Pandey
Head Research
pankaj.pandey@icicisecurities.com
ICICIdirect.com Research Desk,

ICICI Securities Limited,
1st Floor, Akruti Trade Centre,
Road No. 7, MIDC,
Andheri (East)
Mumbai 400 093
research@icicidirect.com
Page 26
ANALYST CERTIFICATION
We /I, Siddhant Khandekar CA-INTER Mitesh Shah MS (Finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report
accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or
view(s) in this report.
Terms & conditions and other disclosures:

ICICI Securities Limited is a Sebi registered Research Analyst having registration no. INH000000990. ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia,
engaged in the business of stock brokering and distribution of financial products. ICICI Securities is a wholly-owned subsidiary of ICICI Bank which is Indias largest private sector bank and has its various
subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. (associates), the details in respect of which are
available on www.icicibank.com.
ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking
and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts
and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.
The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and
meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without
prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securitiesis is under no obligation to update or keep the information
current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended
temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this
company, or in certain other circumstances.
This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This
report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial
instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their
receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific
circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment
objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate
the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any
loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the
risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to
change without notice.
ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment
in the past twelve months.
ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in
respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.
ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned
in the report in the past twelve months.
ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its analysts did not receive any compensation
or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts have any
material conflict of interest at the time of publication of this report.
It is confirmed that Siddhant Khandekar CA-INTER Mitesh Shah MS (Finance), Research Analysts of this report have not received any compensation from the companies mentioned in the report in the
preceding twelve months.
Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.
ICICI Securities or its subsidiaries collectively or Research Analysts do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the
publication of the research report.
Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject
company/companies mentioned in this report.
It is confirmed that Siddhant Khandekar CA-INTER Mitesh Shah MS (Finance), Research Analysts do not serve as an officer, director or employee of the companies mentioned in the report.
ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.
Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.
We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution,
publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities
described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and
to observe such restriction.
Page 27

IDirect HealthCheck Jul16

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

IDirect HealthCheck Jul16

Uploaded by

Copyright:

Available Formats

Monthly Update

July 15, 2016

USFDA plant clearances on the rise

Index Performance as on July 13, 2016

Market cap in | crore

ICICI Securities Ltd. | Retail Equity Research

M&As, demergers, tie-ups and JVs

Cipla in pact with Russian firm for HIV, Hepatitis C drugs

ICICI Securities Ltd. | Retail Equity Research

NPPA cuts prices of 42 drugs

Government relaxes FDI norms in pharma

ICICI Securities Ltd. | Retail Equity Research

Crisil downgrades Ipcas long term debt rating

ICICI Securities Ltd. | Retail Equity Research

Exhibit 2: Patent litigations (12 months)

ICICI Securities Ltd. | Retail Equity Research

Indian Pharma Market

Source: AIOCD data base, ICICIdirect.com Research

Source: AIOCD data base ; As per AIOCD MAT June 2016

Exhibit 4: Companies growth in domestic market in June, 2016

Industry acute to chronic therapy ratio percentage

Exhibit 3: Domestic formulations - growth trend

Top brands in Indian pharma market

IPM grows 6.4% in June

Therapy wise performance (| crore)

Source: AIOCD data base, ICICIdirect.com Research

ICICI Securities Ltd. | Retail Equity Research

Therapy wise performance (| crore)

The Indian pharmaceutical market (IPM) grew 6.4% YoY to | 25411

Exhibit 5: Domestic formulations - quarterly growth trend

IPM grows 6.4% in Q1FY17

Source: AIOCD data base, ICICIdirect.com Research

Exhibit 6: Company wise growth trends in Q1FY17

Source: AIOCD data base, ICICIdirect.com Research

ICICI Securities Ltd. | Retail Equity Research

Acute : Chronic contribution (MAT June16)

Source: NSE, ICICIdirect.com Research

Exhibit 9: Top 10 brands performance

8.9 8.9 9.0 8.8 8.9 8.9

June' 16 June' 15 Var. (%) May' 16 Var. (%)

Sun Pharmaceutical Industries

Source: AIOCD data base, ICICIdirect.com Research

Exhibit 8: Market share in Indian formulations market

Indian Pharma Market

Source: AIOCD data base

Brands contribution to domestic sales (MAT June16)

Exhibit 7: Company growth vis--vis Indian pharma market growth

Source: AIOCD data base

8.4 8.3 8.3

Sun Pharmaceutical Industries

Source: AIOCD data base, ICICIdirect.com Research * Included Ranbaxys sales

Source: AIOCD data base, ICICIdirect.com Research

Exhibit 10: Contribution of therapies to domestic sales (MAT June16)

Exhibit 11: Therapy wise performance

Source: AIOCD data base, ICICIdirect.com Research

ICICI Securities Ltd. | Retail Equity Research

Source: AIOCD data base, ICICIdirect.com Research

Acute : Chronic contribution (MAT June16)

July 15, 2016

Source: NSE, ICICIdirect.com Research

Source: AIOCD data base

Indian Pharma Market

Exhibit 12: Company growth vis--vis Indian pharma market growth